The fact they haven't released guidance probably points towards...

First 21 Last

Share
Profile

Follow
stonkholder

503 Posts.

40

30/07/24

15:27

Post #: 74984467
Share

Originally posted by precis: ↑

Firstly there's another thread about the buyback. Posters have raised the buyback which appears to have stalled even at the current price. The thing worth noting is that the company hasn't released a progress announcement since the 20th of June so we either haven't been buying back or the company doesn't feel like informing shareholders. Either way it's a pretty poor display of how shareholders are being treated so I share the posters' concern.
Then there is the absolutely terrible share price. This is giving me real cause for concern. If a company has over $200 million of work in the pipeline, and has $17 million in the bank and an MC of $23 million you really have to ask if something is going horribly wrong behind the scenes. The first half profit was miniscule and we've been told for years as others have posted, that we are improving margins. Well that hasn't worked so far so I wonder if we are about to announce a loss for the half and a FY loss to boot. This raises the issue of the competency of the Board and Management. if they can't make a substantial profit from $100 million revenue then they are failing to deliver for shareholders. Repetition of last years dividend isn't going to pacify shareholders given we were once 37c and we've had at least 7 years of rhetoric about the move to higher margin work as Stonkholder rightfully states.
So what is going wrong VRS????? And don't say all is fine...blah blah blah because a 4.7c share price is certainly not fine. Nor will the mere mention of a repeat dividend pacify shareholders when they deserve to be treated better. Treated better means better outcomes especially where the bottom line (net profit) is concerned, it means better communication to shareholders when by anyone's measure the current share price is unacceptable, and lastly but importantly, being transparent about where all the money is going when we have repeatedly been receiving $100 million p.a. revenue and the bottom line isn't worth mentioning. Even if something good is around the corner, the current treatment of shareholders is a major failing.

Expand

The fact they haven't released guidance probably points towards a bad result this year. Either another tiny profit or loss.

Management should consider delisting the business and bring it back when it can actually produce some decent net profit margins.

VRS Price at posting: 4.7¢ Sentiment: None Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

DRE

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

Failure to report prompts ASX to impose multiple company suspensions

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 1 more message in this thread...

First 21 Last

Add VRS (ASX) to my watchlist

(20min delay)
Last 4.4¢		Change 0.000(0.00%)		Mkt cap ! $22.40M

Open	High	Low	Value	Volume
4.3¢	4.4¢	4.3¢	$19.36K	440.9K

Buyers (Bids)

No.	Vol.	Price($)
1	127224	4.4¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	42731	2

View Market Depth

No.	Vol.	Price($)
1	127224	0.044
1	4768	0.042
1	50000	0.041
2	282320	0.040
3	611946	0.038

Price($)	Vol.	No.
0.050	42731	2
0.054	50000	1
0.055	150000	1
0.062	100000	1
0.075	299072	1

Last trade - 13.56pm 01/10/2024 (20 minute delay)

VRS (ASX) Chart

The fact they haven't released guidance probably points towards...

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

Failure to report prompts ASX to impose multiple company suspensions

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The fact they haven't released guidance probably points towards...

Top Stories

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

Failure to report prompts ASX to impose multiple company suspensions

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News